What Nouscom does

Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad and potent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity.

Name

Nouscom

Legal name

Nouscom AG

Website

https://nouscom.com/

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Cancer immunotherapy
• Viral vector vaccines
• Neoantigen vaccines
• Immuno-oncology biotech
• Oncolytic virus therapy

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Cancer Immunotherapy Development and Commercialization: Pre-revenue clinical-stage biotech company developing next-generation immunotherapies. Revenue will be generated through commercialization of approved cancer immunotherapies (NOUS-209, NOUS-PEV) upon successful clinical development and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Nouscom develops next-generation viral vectored cancer immunotherapies based on a proprietary heterologous prime/boost platform using Great Ape Adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA). Its clinical candidates include NOUS-209 (off-the-shelf immunotherapy for MSI-H/dMMR tumors and Lynch Syndrome cancer interception), NOUS-PEV (personalized neoantigen vaccine for solid tumors), and NOUS-THV-001 (targeted and armored oncolytic herpes virus), supported by the proprietary VENUS neoantigen prediction algorithm.

Product overview

Nouscom is a clinical-stage biotech company developing next-generation cancer immunotherapies based on proprietary viral vector platforms. The company's portfolio consists of three main products: NOUS-209 (an off-the-shelf immunotherapy encoding 209 shared neoantigens for MSI tumors and Lynch Syndrome cancer interception), NOUS-PEV (a personalized neoantigen vaccine tailored to individual patient tumors using the VENUS algorithm), and NOUS-THV-001 (an armored oncolytic herpes virus for solid tumors). The technology platform combines great ape adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA) vectors with bioinformatics tools for neoantigen prediction. Clinical programs span from early cancer interception in Lynch Syndrome carriers to treatment of metastatic colorectal cancer.

Differentiator

Problem solved

Functional benefit

Brands

• NOUS-209: Off-the-shelf cancer immunotherapy encoding 209 shared frameshift peptide neoantigens for treatment of dMMR/MSI tumors and cancer interception in Lynch Syndrome carriers
• NOUS-PEV
• NOUS-THV-001
• VENUS

Products and services

• NOUS-209

Quantifiable outcome

• 100% of evaluable participants (37/37) developed robust T cell responses against multiple neoantigens in Lynch Syndrome trial
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson Cancer Center serves as the principal investigator site for the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome carriers (NCT05078866). The trial is conducted through the iCAN-PREVENT consortium. Dr. Eduardo Vilar-Sanchez is the principal investigator.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerThe NCI, part of the National Institutes of Health, sponsors clinical trial NCT05078866 under Award Number UG1CA242609. Activities are coordinated through the iCAN-PREVENT consortium.
• Leuven Cancer InstitutecoreStrategic or Co-development PartnerThe Leuven Cancer Institute in Belgium served as principal investigator site for the Phase 1b trial of NOUS-PEV in solid tumors. Dr. Oliver Bechter is the principal investigator.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• BioNTech: Global leader in personalized neoantigen cancer vaccines (e.g., BNT122/RO7198457 with Roche) using mRNA platform. Directly comparable to Nouscom in target biology (personalized neoantigens, MSI/solid tumors) and combination-with-checkpoint-inhibitor strategy, though using a different delivery modality.
• Moderna: Develops mRNA-4157, a personalized neoantigen cancer vaccine in Phase 3 with Merck (KEYNOTE-942). Competes head-to-head with NOUS-PEV in melanoma/NSCLC combination settings with pembrolizumab and is the dominant scale competitor in personalized cancer vaccines.
• Gritstone bio: Develops shared-neoantigen (off-the-shelf, e.g., SLATE) and personalized (autogene cevumeran with Roche) neoantigen cancer vaccines. Highly comparable technology overlap with NOUS-209 (shared FSP antigens) and NOUS-PEV (personalized), targeting similar MSI and solid tumor indications.
• Transgene: French clinical-stage biotech using viral vector (MVA, vaccinia, adenovirus) platforms for cancer immunotherapy, including oncolytic viruses and therapeutic vaccines. Closest direct competitor in terms of viral vector delivery technology and immuno-oncology focus.
• Bavarian Nordic: MVA-based vaccine specialist (MVA-BN platform, JYNNEOS) now expanding into cancer immunotherapy combinations. Comparable in viral vector backbone (MVA) and potential overlap with NOUS-209 prime-boost constructs.
• CureVac: mRNA-based cancer vaccine developer (CV8102, CV9202) with ongoing oncology programs in combination with checkpoint inhibitors and shared antigen approaches. Comparable personalized cancer vaccine peer using a different delivery platform.
• ISA Pharmaceuticals: Clinical-stage biotech developing synthetic long peptide therapeutic cancer vaccines (e.g., ISA101b HPV) with checkpoint combinations. Directly comparable therapeutic vaccine modality targeting defined tumor antigens.
• PsiOxus Therapeutics: Develops oncolytic virus platforms (e.g., enadenotucirev, NG-641) with immune-armoring for solid tumors. Closely comparable to NOUS-THV-001 in the oncolytic virus / TME-modulation space.

Broad incumbents

• Merck KGaA: Operates a viral vector / MVA manufacturing platform through its Life Science and Healthcare divisions and is a major checkpoint inhibitor (avelumab) provider often used in combinations. Comparable on viral vector CMC capabilities and combination immuno-oncology positioning.
• Amgen (Imlygic / BioVex legacy): Through Imlygic (talimogene laherparepvec), Amgen commercializes the only FDA-approved oncolytic HSV. Comparable in oncolytic herpes virus technology and armored immunomodulation strategy to NOUS-THV-001, though serving an established melanoma indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nouscom-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nouscom